## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287										
Estimated average burden										
hours per response	: 0.5									

IRA

D

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*		2. Issuer Name <b>and</b> Ticker or Trading Symbol Vincerx Pharma, Inc. [VINC]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Izumi Raquel E.</u>			<u> </u>	<u></u>	<u> </u>				X	Director	10% 0	Jwner		
(Last) 260 SHERIDAN	(First) N AVENUE, SUIT	(Middle) TE 400			e of Earliest Transa 4/2021	saction (Month/Day/Year)					Officer (give title below) See R	Other below emarks	(specify )	
(Street) PALO ALTO	СА	94306		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indi Line) X	,			
(City)	(State)	(Zip)									Form filed by More than One Reporting Person			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
Date			2. Transact Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year)	3.4. Securities Acquired (A)TransactionDisposed Of (D) (Instr. 3,Code (Instr.5)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)	
Common Stock 08		08/04/2	021		р		1,000	A	\$11.96	1,000	I	By spouse's Rollover		

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned calle 10 0 nute

(e.g., puts, cans, warrants, options, convertible securities)											
Transaction	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and	8. Price of	9. Number of				

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v			Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Explanation of Responses:

Remarks:

Common Stock

President and Chief Operations Officer

## /s/ Raquel E. Izumi

\*\* Signature of Reporting Person Date

1,618,199

08/06/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.